Publicity of prescription drugs in public places, Baekje Shenzhou Cooperation Company fined 400000 yuan
sxhe
发表于 2024-1-19 17:16:46
3668
0
0
On January 19th, Red Star Capital Bureau reported that according to the official website of the Shanghai Municipal Administration for Market Regulation, Baekje Shenzhou (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as "Baekje Shenzhou Biotechnology") has recently been fined 400000 yuan for using advertisements to falsely promote goods or services.
After investigation, it was found that BeiGene Biotech was entrusted by BeiGene (688235. SH; 06160. HK; BGNE. US) to be responsible for the marketing of Pamipali capsules. However, according to public information, there is currently no equity relationship between the two companies.
On January 19th, BeiGene responded to the Red Star Capital Bureau that the company would take it as a warning and strictly comply with relevant laws and regulations in its future work.
On August 18, 2022, BeiGene Biotech held the "Baihuize City Conference" and during the conference, published an advertisement for Pamipali capsules in public areas using a flip flop and promotional flyer as carriers, claiming that "Baihuize (Pamipali) is the only PARP inhibitor approved for the treatment of 3L gBRCAm platinum sensitive and platinum resistant recurrent ovarian cancer; CGCS guidelines recommend Pamipali as the preferred drug for the treatment of recurrent ovarian cancer; the monthly treatment cost for medical insurance patients is only 1929 yuan.".
Data shows that Pamipali capsules are used for the treatment of recurrent advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer patients who have undergone second-line or above chemotherapy and have germline BRCA (gBRCA) mutations.
But as a prescription drug, it can only be advertised in medical and pharmaceutical professional journals jointly designated by the health administrative department of the State Council and the drug regulatory department of the State Council.
On September 21, 2022, with approval, an investigation was filed into the illegal advertising behavior of BeiGene Biotech.
The Market Supervision Administration of Jing'an District, Shanghai believes that Baekje Shenzhou Biotechnology promotes the above-mentioned prescription drugs in public places through the form of pull-up banners and promotional leaflets. The advertising target audience is not specific and will have an impact on the choices of ordinary patients and consumers without professional medical and pharmaceutical knowledge. It cannot guarantee the scientific, correct, reasonable, and safe use of drugs. Finally, BeiGene Biotech received the Administrative Penalty Hearing Notice on December 27, 2023.
Red Star News reporter Deng Lingyao
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Huicheng Technology: Loss of 69.3855 million yuan in the first half of 2024
- Quick news | Starting price of 239900 yuan, Jike 7X releases first week orders exceeding 20000 units
- The first model of NIO's new brand Ledao, L60, has been launched with a price as low as 149900 yuan
- Dozens of AI tools, big promotion of learning and training JD strives to increase the number of small and micro businesses with daily sales exceeding 10000 yuan by more than twice year-on-year on November 11th
- Douyu: Q2 total revenue of 1.032 billion yuan, adjusted net loss of 45.5 million yuan
- Xiaopeng Motors established an automobile sales company in Nanchang with a registered capital of 10 million yuan
- Xiaopeng Motors vigorously poaches Robotaxi talents, with the highest annual salary reaching nearly one million yuan
- Xiaopeng P7+opens pre-sale, starting at 209800 yuan
- Continue repurchasing! BOSS Direct Hiring spent 17.78 million yuan to repurchase 336000 shares
- Entering the real world of intelligent cars from the future, the Jike MIX is launched with a starting price of 279900 yuan
-
【英偉達の需要が高すぎる?SKハイニックス:黄仁勲がHBM 4チップの6カ月前納入を要求!】SKハイニックスの崔泰源(チェ・テウォン)会長は月曜日、インビダーの黄仁勲(ファン・インフン)CEOが同社の次世代高帯域 ...
- 琳271
- 前天 17:54
- 支持
- 反对
- 回复
- 收藏
-
ファイザーが前立腺がんを治療する革新薬テゼナ& ;reg;(TALZENNA®,一般名:トルエンスルホン酸タラゾールパーリカプセル)は2024年10月29日に国家薬品監督管理局(NMPA)の承認を得て、HRR遺伝子突然変異 ...
- 什么大师特
- 昨天 17:41
- 支持
- 反对
- 回复
- 收藏
-
南方財経は11月5日、中央テレビのニュースによると、現地時間11月5日、米ボーイング社のストライキ労働者が59%の投票結果で新たな賃金協定を受け入れ、7週間にわたるストライキを終えた。ストライキ労働者は11月12 ...
- Dubssgshbsbdhd
- 昨天 16:27
- 支持
- 反对
- 回复
- 收藏
-
【マスクはテスラが携帯電話を作ることに応えた:作れるが作らないアップルとグーグルが悪さをしない限り】現地時間11月5日、有名ポッドキャストのジョローガン氏のインタビューに応じ、「携帯電話を作るのは私たち ...
- 波大老师
- 昨天 14:41
- 支持
- 反对
- 回复
- 收藏